| # | Title | Journal | Year | Citations |
|---|
| 1 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2017 | 1,376 |
| 2 | ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach | Annals of Oncology | 2019 | 614 |
| 3 | Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study | Annals of Oncology | 2019 | 456 |
| 4 | Defining the Roles of Nucleotide Excision Repair and Recombination in the Repair of DNA Interstrand Cross-Links in Mammalian Cells | Molecular and Cellular Biology | 2000 | 401 |
| 5 | Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer | British Journal of Cancer | 2004 | 351 |
| 6 | APOBEC-Mediated Cytosine Deamination Links PIK3CA Helical Domain Mutations to Human Papillomavirus-Driven Tumor Development | Cell Reports | 2014 | 309 |
| 7 | Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours | Current Biology | 1999 | 279 |
| 8 | Pan-cancer deconvolution of tumour composition using DNA methylation | Nature Communications | 2018 | 205 |
| 9 | The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2 | Molecular Cell | 2017 | 189 |
| 10 | Predicting biomarkers for ovarian cancer using gene-expression microarrays | British Journal of Cancer | 2004 | 176 |
| 11 | PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions | British Journal of Cancer | 2016 | 163 |
| 12 | Repair of Intermediate Structures Produced at DNA Interstrand Cross-Links in Saccharomyces cerevisiae | Molecular and Cellular Biology | 2000 | 145 |
| 13 | The involvement of p38 mitogen-activated protein kinase in the α-melanocyte stimulating hormone (α-MSH)-induced melanogenic and anti-proliferative effects in B16 murine melanoma cells | FEBS Letters | 2000 | 140 |
| 14 | DNA Repair capacity and cisplatin sensitivity of human testis tumour cells | International Journal of Cancer | 1997 | 120 |
| 15 | Kaposi's Sarcoma–Associated Herpesvirus: A New DNA Tumor Virus | Annual Review of Medicine | 2001 | 102 |
| 16 | A bird's eye view of the glutathione transferase field | Chemico-Biological Interactions | 2001 | 102 |
| 17 | Management of Platinum-Sensitive Recurrent Ovarian Cancer | Seminars in Oncology | 2006 | 94 |
| 18 | Antibody-directed enzyme prodrug therapy (ADEPT) for cancer | Expert Opinion on Biological Therapy | 2004 | 85 |
| 19 | Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer | JAMA Oncology | 2021 | 82 |
| 20 | Modulation of DNA Repair In vitro after Treatment with Chemotherapeutic Agents by the Epidermal Growth Factor Receptor Inhibitor Gefitinib (ZD1839) | Clinical Cancer Research | 2004 | 79 |
| 21 | Targeted photodynamic therapy with multiply‐loaded recombinant antibody fragments | International Journal of Cancer | 2008 | 75 |
| 22 | Cancer stem cells and radiotherapy | International Journal of Radiation Biology | 2009 | 75 |
| 23 | Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT) | British Journal of Cancer | 2004 | 70 |
| 24 | Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2020 | 70 |
| 25 | Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial | Lancet Oncology, The | 2022 | 70 |
| 26 | Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin | Biochemical Journal | 2000 | 69 |
| 27 | A Phase I Study of Single Administration of Antibody-Directed Enzyme Prodrug Therapy with the Recombinant Anti–Carcinoembryonic Antigen Antibody-Enzyme Fusion Protein MFECP1 and a Bis-Iodo Phenol Mustard Prodrug | Clinical Cancer Research | 2006 | 69 |
| 28 | DNA Interstrand Cross-Link Repair in the Saccharomyces cerevisiae Cell Cycle: Overlapping Roles for PSO2 ( SNM1 ) with MutS Factors and EXO1 during S Phase | Molecular and Cellular Biology | 2005 | 68 |
| 29 | Production of recombinant protein in Pichia pastoris by fermentation | Nature Protocols | 2006 | 68 |
| 30 | Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans | Human Molecular Genetics | 2015 | 67 |
| 31 | Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion | British Journal of Cancer | 2017 | 66 |
| 32 | Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS | NMR in Biomedicine | 2002 | 65 |
| 33 | Electrohydrodynamic encapsulation of cisplatin in poly (lactic-co-glycolic acid) nanoparticles for controlled drug delivery | Nanomedicine: Nanotechnology, Biology, and Medicine | 2016 | 64 |
| 34 | Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody | Clinical Cancer Research | 2000 | 59 |
| 35 | Phase III Trial of Epirubicin Plus Paclitaxel Compared With Epirubicin Plus Cyclophosphamide As First-Line Chemotherapy for Metastatic Breast Cancer: United Kingdom National Cancer Research Institute Trial AB01 | Journal of Clinical Oncology | 2005 | 57 |
| 36 | Performance of novel high throughput multi electrospray systems for forming of polymeric micro/nanoparticles | Materials and Design | 2017 | 54 |
| 37 | Engineering Antibodies for Clinical Applications in Cancer | Tumor Biology | 2004 | 53 |
| 38 | Transcriptional Regulation of Topoisomerase IIα at Confluence and Pharmacological Modulation of Expression bybis-Benzimidazole Drugs | Molecular Pharmacology | 2001 | 51 |
| 39 | Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer | British Journal of Surgery | 2006 | 50 |
| 40 | DNA repair after irradiation in glioma cells and normal human astrocytes | Neuro-Oncology | 2007 | 49 |
| 41 | Functionalised cyclopentadienyl titanium compounds as potential anticancer drugs | Dalton Transactions | 2007 | 49 |
| 42 | DNA Replication Licensing Factors and Aurora Kinases are Linked to Aneuploidy and Clinical Outcome in Epithelial Ovarian Carcinoma | Clinical Cancer Research | 2007 | 46 |
| 43 | Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent | Cancer Research | 1999 | 46 |
| 44 | Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib | JAMA Oncology | 2021 | 44 |
| 45 | Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts | Biochemical Journal | 2000 | 43 |
| 46 | Tumour targeting of humanised cross-linked divalent-fab′ antibody fragments: a clinical phase I/II study | British Journal of Cancer | 2002 | 42 |
| 47 | A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex | Cancer Research | 2001 | 42 |
| 48 | Electrohydrodynamic fabrication of core–shell PLGA nanoparticles with controlled release of cisplatin for enhanced cancer treatment | International Journal of Nanomedicine | 2017 | 39 |
| 49 | Somatostatin Analogs Treated Small Intestinal Neuroendocrine Tumor Patients Circulating MicroRNAs | PLoS ONE | 2015 | 37 |
| 50 | DNA Repair in Cisplatin-Sensitive and Resistant Human Cell Lines Measured in Specific Genes by Quantitative Polymerase Chain Reaction | Biochemical Pharmacology | 1996 | 36 |
